

SACHS ASSOCIATES 4th ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM

1st June 2018 | Waldorf Astoria Chicago Hotel | USA

07:20 Registration & Coffee



08:10 Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates

08:20 **Industry Roundtable: Pharma-Biotech Pipeline**
Chaired by:
Jeffrey Bockman, EVP, Oncology Practice Head, **Defined Health**, a **Cello Health** business
Panelists:
Asthika Goonewardene, Senior Biotech Analyst, **Bloomberg Intelligence**
Francis Kern, Executive Director, Oncology Search & Evaluation, Global Business Development, **Daiichi Sankyo, Inc.**
Ji Li, EVP, Global Head of Business Development, **BeiGene Ltd.**
John DeYoung, Vice President, Oncology Business Development, **Pfizer, Inc.**
Peter Thompson, Private Equity Partner, **OrbiMed Advisors, LLC**

09:00 **DealMaking and M&A Panel**
Co-Chaired by:
Jonathan Kfoury, Managing Director, **L.E.K. Consulting**
Michael Margolis, Co-Head of Healthcare Investment Banking, **Oppenheimer & Co., Inc.**
Panelists:
Andrew Hass, Senior Advisor, Oncology External Innovation, **Eli Lilly & Co.**
Chris Sheldon, Head of Oncology Search & Evaluation, **AstraZeneca**
Guillaume Vignon, Senior Vice President Business Development, **BeiGene Ltd.**
Matthias Müllenbeck, Director Global Oncology L&DB, **Merck KGaA**

09:40 **"Drug Chess: Planning a Few Moves Ahead of the Competition"**
 by Peter Kolchinsky, Portfolio Manager & Managing Director, RA Capital Management, LLC

10:00 Coffee Break

10:20 **"Selective AXL Inhibition as a Potential Cornerstone of Combination Cancer Therapy"**
 by Richard Godfrey, CEO, BerGenBio ASA

10:40 **Latest Developments in IO & Combination Therapies Panel**
Co-Chaired by:
Mark Breidenbach, Executive Director & Senior Analyst, Biotechnology, **Oppenheimer & Co., Inc.**
William Kuziel, Oncology Search & Evaluation, Global Business Development, **Daiichi Sankyo, Inc.**
Panelists:
Carlos de Sousa, CEO, **Immunicum AB**
John Haurum, CEO, **F-star Biotechnology Ltd.**
Lisa Decker, Vice President, Business Development, **Nektar Therapeutics**
Loic Vincent, Head Oncology & Immunology Research Partnerships, **Takeda Pharmaceuticals International**
Takashi Kei Kishimoto, CSO, **Selecta Biosciences, Inc.**

11:20 **Cancer Vaccines & Neo Antigens: Evaluating Latest Progress Panel**
Chaired by:
Matthias Müllenbeck, Director Global Oncology L&BD, **Merck KGaA**
Panelists:
Frederic Ors, CEO, **Immunovaccine, Inc.**
Igor Matushansky, CMO, Global Head Research & Development, **Hookipa Biotech AG**
Karin Jooss, EVP of Research & CSO, **Gritstone Oncology**
Marc Dechamps, Acting CEO, **eTheRNA immunotherapies NV**
Pamela Carol, SVP, Immuno-Oncology, **Genocea Biosciences, Inc.**

PR Companies Track A		PR Companies Track B		PR Companies Track C	
Moderated by		Moderated by:		Moderated by:	
Raghuram Selvaraju , H.C. Wainwright & Co., LLC		Kumaraguru Raja , Brookline Capital Markets		Robin Davison , New Science Global Healthcare Fund	
12:20	TapImmune, Inc. [NASDAQ: TPIV]	12:00	Selecta Biosciences, Inc. [NASDAQ: SELB]	12:00	Lycera
				12:10	ISA Pharmaceuticals B.V.
				12:20	Madison Vaccines Incorporated
				12:30	VLP Therapeutics

12:40 Networking Lunch

12:40	Networking Lunch				
13:40	Advances in Cell & Gene Therapies Panel <i>Co-Chaired by:</i> Axel Hoos , SVP, TA Head of Oncology R&D, GlaxoSmithKline Gregory Frost , Managing Director, F1BioVentures, LLC <i>Panelists:</i> Charles Wilson , President & CEO, Unum Therapeutics, Inc. Helen Tayton-Martin , CBO, Adaptimmune Ltd. Peter Hoang , President & CEO, TapImmune, Inc. Raghuram Selvaraju , Managing Director, Senior Healthcare Analyst, H.C. Wainwright & Co., LLC Timothy Herpin , CBO, Caribou Biosciences, Inc.				
PR Companies Track D Moderated by: Juan Pedro Serrate , Edison Group		PR Companies Track E Moderated by: Leonards Sachs , Sachs Associates		PR Companies Track F Moderated by: Robin Davison , New Science Global Healthcare Fund	
14:40	OSE Immunotherapeutics [EPA: OSE]	14:40	Genocea Biosciences, Inc. [NASDAQ: GNCA]	14:40	F-star Biotechnology Ltd.
15:00	Selvita S.A. [WSE: SLV]	15:00	ACM Biolabs Pte Ltd.	15:00	Numab Therapeutics AG
15:20	Immunovaccine, Inc. [TSE: IMV]	15:20	Hookipa Biotech AG	15:20	Triumvira Immunologics, Inc.
15:40	Hemispherx Biopharma, Inc. [NYSEAMERICAN: HEB]	15:40	eTheRNA immunotherapies NV	15:40	Medicenna Therapeutics, Corp. [TSE: MDNA]
16:00	Coffee Break				
16:10	Early Stage Innovation Panel <i>Chaired by:</i> Robert Silverman , Personalized Healthcare (PHC) Business Strategy & Partnering, Roche Innovation Center <i>Panelists:</i> Gary Sclar , Vice President, Dana-Farber Innovations, Dana-Farber Cancer Institute Hilary Hehman , Director, Partnerships & Alliances, Fred Hutchinson Cancer Research Center Lee Greenberger , CSO, The Leukemia & Lymphoma Society (LLS) Nathan Gianneschi , Founder, Vybyl Biopharma Robert Radinsky , VP, Oncology Scientific Innovation, Johnson & Johnson Innovation				
16:50	Investor Roundtable <i>Co-Chaired by:</i> Bibhash Mukhopadhyay , Principal, NEA Boris Peaker , Managing Director, Biotechnology Equity Research, Cowen, Inc. <i>Panelists:</i> Arjun Goyal , Co-Founder & Managing Director, Vida Ventures Brad Loncar , Private Investor, Portfolio Manager, Loncar Investments, LLC Luke Li , Partner & Managing Director, Ally Bridge Group Yogendra Sauntharajah , Professor of Medicine, Staff Physician & Co-Leader of the Developmental Therapeutics Program, Cleveland Clinic Yuwen Liu , Founding Partner & CEO, Bohe Angel Fund				
17:30	Networking Reception				
18:30	End of the 4th IOBDLI Forum				

Silver Sponsor:



Supported by:



|Citigate Dewe Rogerson

